Candel Therapeutics, Inc. CADL Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $119.73M+16.6% | $102.65M+190% | $35.41M-49.5% | $70.06M-15.2% | ||
| $416K+56.4% | $266K0.0% | $266K0.0% | $266K-37.3% | ||
| $1.66M+44.2% | $1.15M-16.9% | $1.38M-26.7% | $1.89M-18.1% | ||
| $121.39M+16.9% | $103.8M+182% | $36.8M-48.9% | $71.95M-15.3% | ||
| $1.64M-25.1% | $2.19M-31.7% | $3.21M-27.5% | $4.42M+15.3% | ||
| $1.66M+206% | $542K-33.6% | $816K-22.7% | $1.06M— | ||
| $87K+38.1% | $63K-45.7% | $116K— | —— | ||
| $125.2M+17.2% | $106.87M+159% | $41.2M-47.0% | $77.69M-12.9% | ||
| $4.96M+245% | $1.44M-17.5% | $1.74M-59.6% | $4.32M+25.3% | ||
| $89K— | $0-100% | $4.36M+8,975% | $48K-85.6% | ||
| $89K— | $0— | —— | $144K— | ||
| $0-100% | $9.9M+11.3% | $8.89M— | —— | ||
| $445K-21.4% | $566K+10.3% | $513K+10.6% | $464K— | ||
| $9M-76.0% | $37.53M+165% | $14.18M+153% | $5.62M+4.7% | ||
| $1.01M+15.9% | $870K+15.8% | $751K+15.9% | $648K+15.7% | ||
| $1.46M+258% | $407K-58.2% | $973K-34.5% | $1.49M— | ||
| $1.9M+95.7% | $973K-34.5% | $1.49M-23.8% | $1.95M— | ||
| $73.27M+80.7% | $40.54M+42.5% | $28.46M-5.1% | $29.98M+19.6% | ||
| $550K+17.3% | $469K+61.7% | $290K0.0% | $290K+1.4% | ||
| $282.21M+9.2% | $258.51M+72.4% | $149.93M+2.0% | $146.96M+2.0% | ||
| -$230.39M-19.9% | -$192.21M-40.3% | -$137.03M-38.3% | -$99.09M-23.4% | ||
| $448K0.0% | $448K0.0% | $448K0.0% | $448K— | ||
| $51.92M-21.7% | $66.33M+420% | $12.75M-73.3% | $47.71M-25.6% | ||
| $125.2M+17.2% | $106.87M+159% | $41.2M-47.0% | $77.69M-12.9% | ||
| $1.66M+206% | $542K-33.6% | $816K-22.7% | $1.06M— | ||
| $1.66M+206% | $542K-33.6% | $816K-22.7% | $1.06M— | ||
| $87K+38.1% | $63K-45.7% | $116K— | —— | ||
| $1.66M+206% | $542K-33.6% | $816K-22.7% | $1.06M— | ||
| $7.33M+43.4% | $5.11M+17.4% | $4.36M-7.8% | $4.72M+37.4% | ||
| $7.33M+43.4% | $5.11M+17.4% | $4.36M-7.8% | $4.72M+37.4% | ||
| $89K— | $0— | —— | $48K-85.6% | ||
| $89K— | $0— | —— | $144K— | ||
| $2.91M-75.2% | $11.74M+5.5% | $11.13M+328% | $2.6M+364% | ||
| $282.21M+9.2% | $258.51M+72.4% | $149.93M+2.0% | $146.96M+2.0% | ||
| $550K+17.3% | $469K+61.7% | $290K0.0% | $290K+1.4% | ||
| $448K0.0% | $448K0.0% | $448K0.0% | $448K— | ||
| $15.6M— | $0-100% | $916K-51.3% | $1.88M-89.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Candel Therapeutics, Inc.'s total assets?
- Candel Therapeutics, Inc. (CADL) holds $201.9M in total assets, up 110.5% year over year.
- How much debt does Candel Therapeutics, Inc. have?
- Candel Therapeutics, Inc. carries $2.8M in total debt against $138.0M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Candel Therapeutics, Inc. have?
- Candel Therapeutics, Inc. holds $194.8M in cash and equivalents.
- Can Candel Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 28.05 — current assets exceed current liabilities.
- Where does Candel Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
